SSc-ILD stands for systemic sclerosis-associated interstitial lung disease, a condition in which the autoimmune disorder scleroderma triggers progressive scarring inside the lungs. It is the most serious and life-threatening complication of systemic sclerosis, driven by a collision of immune activation, blood vessel injury, and runaway tissue repair that gradually replaces healthy lung with stiff, fibrous tissue.1PubMed Central. Advances in the Molecular Mechanisms of Pulmonary Fibrosis in Systemic Sclerosis: A Comprehensive Review How quickly it progresses, which treatments work best, and what it means for day-to-day life vary widely from person to person, making early detection and tailored management especially important.
How Scleroderma Leads to Lung Scarring
Systemic sclerosis (often called scleroderma) is a rare autoimmune disease known for thickening and hardening the skin, but it can affect virtually any internal organ. In the lungs, the disease plays out in three overlapping stages. First, blood vessels in the lung tissue become damaged early on. Second, the immune system ramps up inflammation around those injured vessels. Third, cells called fibroblasts go into overdrive, producing excess collagen and other structural proteins that stiffen the lung’s delicate air sacs.2Current Treatment Options in Rheumatology. Molecular Mechanisms Underlying Systemic Sclerosis–Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: an Update The result is irreversible structural damage: the lungs lose their ability to stretch, and gas exchange suffers because oxygen can no longer pass efficiently from air sacs into the bloodstream.1PubMed Central. Advances in the Molecular Mechanisms of Pulmonary Fibrosis in Systemic Sclerosis: A Comprehensive Review
This fibrotic process shares some features with idiopathic pulmonary fibrosis (IPF), a separate disease with no known autoimmune trigger. In both conditions, fibroblast activation and the buildup of scar-forming cells called myofibroblasts are the final common pathway. But the starting point differs: in SSc-ILD, vascular damage comes first and multiple cell types participate in the inflammatory cascade, whereas IPF tends to begin with repeated microscopic injuries to the lung lining itself.2Current Treatment Options in Rheumatology. Molecular Mechanisms Underlying Systemic Sclerosis–Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: an Update
Who Is Most at Risk
Not everyone with scleroderma develops clinically significant lung disease. Several factors raise the likelihood. The antibodies circulating in your blood are among the strongest predictors. People who test positive for anti-Scl-70 (also called anti-topoisomerase I) antibodies face a higher risk of developing ILD and tend to experience a faster decline in lung function, particularly during the first decade after scleroderma diagnosis.3PubMed Central. The clinical relevance of autoantibodies in scleroderma 4Rheumatology Advances in Practice. Clinical phenotype in scleroderma patients based on autoantibodies By contrast, people with anticentromere antibodies (ACA) are more likely to have limited skin involvement and less lung disease.
Scleroderma is traditionally divided into two subtypes: diffuse (widespread skin thickening, often rapid onset) and limited (skin changes mostly in the hands and face, slower course). You might assume diffuse disease always means worse lungs, but it is not that simple. Data from the Scleroderma Lung Study showed that baseline lung inflammation and breathing test results were similar in both groups, though CT-scored fibrosis was actually worse in limited SSc patients in that cohort, while diffuse SSc patients fared worse on measures of skin involvement, physical function, and quality of life.5Annals of the Rheumatic Diseases. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis The takeaway is that ILD screening matters regardless of subtype.
Symptoms and Early Warning Signs
The earliest symptom is usually breathlessness on exertion, the kind you first notice climbing stairs or walking uphill. Because scleroderma can also cause muscle weakness, joint stiffness, and fatigue, shortness of breath is easy to chalk up to deconditioning or other aspects of the disease. A dry, nonproductive cough is another common early sign. As lung scarring advances, breathlessness becomes noticeable during lighter activities and eventually at rest. Some people also develop chest tightness.
SSc-ILD has a significant impact on quality of life that extends beyond just feeling winded. Validated questionnaires used in research capture three distinct dimensions of the burden: chest symptoms, the physical limitations caused by breathlessness, and psychological distress including anxiety about disease progression.6Journal of Scleroderma and Related Disorders. Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters Because symptoms creep in gradually, many patients have already lost measurable lung function by the time they report trouble breathing, which is why routine screening with imaging and breathing tests is standard practice in scleroderma care.
How SSc-ILD Is Detected and Monitored
High-resolution CT (HRCT) of the chest is the primary tool for diagnosing SSc-ILD. The most common pattern on the scan is nonspecific interstitial pneumonia (NSIP), found in roughly seven out of ten patients, characterized by hazy ground-glass opacities along the outer edges of the lower lungs and areas of traction bronchiectasis where scarred lung tugs on the airways.7Journal of Radiology and Oncology. HRCT imaging features of systemic sclerosis-associated interstitial lung disease 8PubMed Central. High resolution computed tomography in systemic sclerosis: From diagnosis to follow-up A smaller fraction shows a usual interstitial pneumonia (UIP) pattern, and rarer patterns including organizing pneumonia and diffuse alveolar damage can also occur.9PubMed Central. Interstitial lung disease pathology in systemic sclerosis Compared with IPF, SSc-ILD scans tend to show a larger proportion of ground-glass opacity relative to coarse fibrosis, a distinction that can help radiologists tell them apart.10PubMed. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia
One practical question clinicians face is how much lung is involved. A simplified scoring approach divides the picture into whether more or less than 20-25% of the lung is affected on HRCT. That threshold helps stratify risk: patients with extensive disease tend to decline faster and may warrant more aggressive treatment earlier.11PubMed Central. Imaging Lung Disease in Systemic Sclerosis
Pulmonary function tests (PFTs) complement imaging. The two key numbers are forced vital capacity (FVC), which reflects how much air you can blow out, and diffusing capacity for carbon monoxide (DLCO), which measures how well oxygen crosses from lung into blood. In many SSc-ILD patients, FVC remains relatively stable over the first year or two, while DLCO drops earlier and more steeply. A decline in DLCO of more than 15% over 12 months has strong predictive value for worsening disease.12PubMed Central. Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis–Related Interstitial Lung Disease Patients with higher fibrosis scores on CT who are still early in their disease course tend to lose FVC fastest, reinforcing the value of combining imaging and breathing tests rather than relying on either alone.13PubMed Central. Clinical Course of Lung Physiology in Patients with Scleroderma and Interstitial Lung Disease: Analysis of the Scleroderma Lung Study Placebo Group
Blood Biomarkers Worth Knowing About
Beyond standard antibodies, researchers are investigating blood-based biomarkers that could flag ILD activity without repeated CT scans. KL-6, a protein shed by damaged lung cells, shows a strong inverse relationship with FVC and is significantly higher in patients whose ILD is actively progressing.14PubMed Central. Role of serum biomarkers KL-6, SP-D and CCL-18 in assessing interstitial lung disease in systemic sclerosis: A prospective observational study from India SP-D, another lung-derived protein, correlates with the extent of disease on CT and with skin thickness scores, while also running higher in people with SSc-ILD than in scleroderma patients without lung involvement.14PubMed Central. Role of serum biomarkers KL-6, SP-D and CCL-18 in assessing interstitial lung disease in systemic sclerosis: A prospective observational study from India None of these markers have replaced imaging or PFTs in routine care yet, but they may eventually help doctors decide when to repeat a CT scan or escalate treatment.
Immunosuppressive Treatments
Treatment of SSc-ILD has historically centered on tamping down the overactive immune response. The two most studied immunosuppressants are cyclophosphamide and mycophenolate mofetil (often called MMF or CellCept). In the landmark Scleroderma Lung Study II, both drugs improved lung function over two years. MMF did not prove superior in efficacy, but it caused fewer side effects and was better tolerated, which has made it the first-line choice for most rheumatologists today.15PubMed Central. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial A subsequent meta-analysis pooling multiple studies confirmed that the two drugs produce comparable improvements in FVC, while adverse events are less common with MMF.16PubMed. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis
Biologic Therapies
When SSc-ILD progresses despite standard immunosuppression, biologic drugs offer another avenue. Rituximab, which depletes B cells, and tocilizumab, which blocks the inflammatory signal interleukin-6, have both been studied in this setting. A real-world cohort analysis found that both drugs stabilized lung function in patients who had been declining beforehand. Before treatment, patients in both groups were losing roughly 3% of their FVC per year; after starting either biologic, FVC stabilized or improved slightly.17PubMed Central. Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis A separate meta-analysis of rituximab use specifically showed a meaningful improvement in FVC at roughly six months to a year after treatment, along with improvements in skin thickening scores.18PubMed Central. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis
A large real-world comparison from the European Scleroderma Trials and Research (EUSTAR) database compared tocilizumab, rituximab, MMF, and cyclophosphamide head-to-head and found no statistically significant difference among the four in terms of FVC change.19PubMed. Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database That finding is reassuring in one sense: it means doctors can choose based on side-effect profile, patient preference, and other organ involvement rather than feeling locked into one drug. But it also underscores that no single agent is dramatically better than the rest for preserving lung function.
Antifibrotic Therapy With Nintedanib
Nintedanib, originally approved for IPF, became the first drug specifically approved for SSc-ILD after the SENSCIS trial showed it slowed the annual rate of FVC loss. Patients receiving nintedanib lost about 52 ml of FVC per year compared with about 93 ml per year in the placebo group, a roughly 44% reduction in the rate of decline.20PubMed. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease The drug works by blocking pathways that drive fibroblast activity rather than by suppressing the immune system, so it targets the scarring process from a different angle than immunosuppressants.
Because the mechanisms are complementary, many patients now receive nintedanib alongside mycophenolate. A subgroup analysis of SENSCIS participants who were already on MMF at baseline showed that nintedanib still provided additional benefit in slowing FVC decline on top of the immunosuppressive therapy.21The Lancet Respiratory Medicine. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate at baseline: a subgroup analysis of the SENSCIS trial The main side effect is diarrhea, which can be significant enough that some patients need dose adjustments.
Stem Cell Transplantation for Severe Disease
For patients with aggressive, rapidly progressing scleroderma, autologous hematopoietic stem cell transplantation (HSCT) is the most intensive option on the table. The idea is to wipe out the malfunctioning immune system and rebuild it from the patient’s own stem cells. In the SCOT trial, transplant patients had markedly better long-term outcomes than those receiving cyclophosphamide alone: at six years, event-free survival was about 74% after transplant versus 47% with cyclophosphamide, and overall survival was 86% versus 51%.22PubMed Central. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma Lung function, skin scores, and CT fibrosis measures all improved after transplant in long-term follow-up data from multiple centers.23Annals of the Rheumatic Diseases. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study
The catch is treatment-related mortality. In the SCOT trial, transplant-related deaths occurred at a rate of about 6% at six years, compared with 0% in the cyclophosphamide arm.22PubMed Central. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma A more recent single-center study reported an even higher transplant-related mortality rate of nearly 19%, though the overall cohort was small.24Rheumatology. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy Risk factors for fatal complications include male sex, reduced heart pumping function, and older age.23Annals of the Rheumatic Diseases. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study Reassuringly, treatment-related deaths have decreased over time as centers have gained experience with patient selection and conditioning regimens. HSCT is reserved for carefully selected patients with severe, progressive disease, and the decision involves weighing a real upfront risk against a substantial long-term survival benefit.
Lung Transplantation
When SSc-ILD progresses to end-stage lung failure despite medical therapy, lung transplantation becomes an option. There has long been concern that scleroderma patients would do poorly after transplant because the disease affects the esophagus and gut, raising the risk of acid reflux damaging the new lungs. In practice, the outcomes have been better than feared. One comprehensive single-center study reported one-, three-, and five-year survival rates of 94%, 77%, and 70% after lung transplant in SSc patients, which were comparable to survival in other transplant populations, even though roughly 60% of the scleroderma group had severe esophageal dysfunction.25PubMed Central. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience A matched-cohort study confirmed similar survival, similar rates of chronic graft rejection, and even lower rates of acute rejection in SSc-ILD transplant recipients compared with controls.26PubMed Central. Outcomes in Systemic Sclerosis-related Lung Disease following Lung Transplantation
These findings have gradually shifted transplant center attitudes. Many programs that once considered scleroderma a relative contraindication now evaluate these patients on a case-by-case basis, paying close attention to esophageal testing and other organ involvement but no longer excluding patients from consideration solely because of the scleroderma diagnosis.
The Overlap With Pulmonary Hypertension
SSc-ILD does not exist in isolation. One of the most dangerous complications is pulmonary hypertension (PH), high blood pressure in the arteries feeding the lungs. This can arise because scarred, stiff lung tissue forces the heart’s right side to work harder, or because scleroderma directly damages the pulmonary blood vessels. In a study of SSc-ILD patients who underwent right heart catheterization, about a third had confirmed PH.27PubMed Central. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis In a larger registry, roughly 7% of all scleroderma patients met criteria for combined pulmonary arterial hypertension and ILD, and this overlap group was more frequently male, more likely to have diffuse skin disease, and had higher inflammatory markers than the overall cohort.28PubMed Central. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis
What makes the overlap clinically tricky is that SSc-PAH and SSc-ILD share similar but distinct molecular profiles, meaning they are not just two expressions of the same process.29PubMed Central. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease That matters for treatment: medications that help one condition may not help the other, and managing both simultaneously requires careful coordination between rheumatology and pulmonology teams. A disproportionate drop in DLCO relative to FVC can be an early clue that pulmonary hypertension is developing on top of ILD.
The Gastroesophageal Connection
Most people with scleroderma have some degree of esophageal dysfunction, and mounting evidence suggests this is not just a parallel nuisance but may actively worsen lung disease. A study using quantitative CT analysis found that higher gastroesophageal reflux scores at baseline were independently associated with greater progression of lung fibrosis over two years, even after adjusting for treatment and initial disease severity.30PubMed Central. Association of symptoms of gastroesophageal reflux, esophageal dilation and progression of systemic sclerosis-related interstitial lung disease The suspected mechanism is microaspiration: tiny amounts of stomach contents repeatedly reaching the lungs and triggering inflammation. This is an area where aggressive reflux management, including proton pump inhibitors and sometimes surgical intervention, may have implications beyond just digestive comfort.
Pulmonary Rehabilitation
Drug therapy addresses the underlying disease, but pulmonary rehabilitation addresses how you live with it day to day. Structured exercise programs designed for people with chronic lung disease can improve breathlessness, walking capacity, and quality of life in SSc-ILD. A study of home-based pulmonary rehabilitation in scleroderma patients found significant improvements in dyspnea and quality-of-life scores compared with a standard program.31European Respiratory Journal. Pulmonary rehabilitation in Systemic sclerosis A systematic review of pulmonary rehabilitation in connective tissue disease-associated ILD more broadly reported moderate-level evidence supporting benefits for lung function, exercise capacity, quality of life, and fatigue, though evidence for improvements in muscle strength was more limited.32PubMed Central. Pulmonary rehabilitation in connective tissue disease-associated interstitial lung disease: A systematic review The practical barrier is access: scleroderma patients often have joint and skin limitations that make standard rehab programs difficult, so home-based or adapted programs may be more realistic for many.
Emerging Approaches on the Horizon
The treatment landscape is still evolving. Current clinical trials are testing combination strategies that pair immunosuppressants with antifibrotics from the start rather than adding them sequentially. More experimental approaches include chimeric antigen receptor (CAR) T-cell therapy, which has drawn attention for refractory autoimmune diseases after dramatic case reports in lupus and is now being explored in scleroderma as well. Researchers are also investigating novel molecular targets beyond the pathways addressed by existing drugs, aiming to interrupt fibrosis at earlier stages or through alternative mechanisms. The pace of clinical trials in SSc-ILD has accelerated considerably in the last five years, a shift driven partly by the success of nintedanib in demonstrating that well-designed trials in this population can produce clear results and regulatory approvals.